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Abstract
Amphotericin B (AMB) is used most commonly in severe systemic life-threatening fungal
infections. There is currently an unmet need for an efficacious (AMB) formulation amenable to
oral administration with better bioavailability and lower nephrotoxicity. Novel PEGylated
polylactic-polyglycolic acid copolymer (PLGA-PEG) nanoparticles (NPs) formulations of AMB
were therefore studied for their ability to kill Candida albicans (C. albicans). The antifungal
activity of AMB formulations was assessed in C. albicans. Its bioavalability was investigated in
nine groups of rats (n¼ 6). Toxicity was examined by an in vitro blood hemolysis assay, and in
vivo nephrotoxicity after single and multiple dosing for a week by blood urea nitrogen (BUN)
and plasma creatinine (PCr) measurements. The MIC of AMB loaded to PLGA-PEG NPs against
C. albicans was reduced two to threefold compared with free AMB. Novel oral AMB delivery
loaded to PLGA-PEG NPs was markedly systemically available compared to Fungizone in rats.
The addition of 2% of GA to the AMB formulation significantly (p50.05) improved the
bioavailability from 1.5 to 10.5% and the relative bioavailability was4790% that of Fungizone.
The novel AMB formulations showed minimal toxicity and better efficacy compared to
Fungizone . No nephrotoxicity in rats was detected after a week of multiple dosing of AMB NPs
based on BUN and PCr, which remained at normal levels. An oral delivery system of
AMB-loaded to PLGA-PEG NPs with better efficacy and minimal toxicity was formulated. The
addition of glycyrrhizic acid (GA) to AMB NPs formulation resulted in a significant oral
absorption and improved bioavailability in rats.
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Introduction
Amphotericin B (AMB) has been the gold standard treatment
for severe systemic life-threatening fungal infections since
1959 (Bekersky et al., 1999; Cifani et al., 2012). It has been
used as the first-line treatment for visceral leishmaniasis, a
life-threatening parasitic disease, in the endemic area of
Bihar, India (Sundar et al., 2010). Unfortunately, AMB
formulations are only available for parenteral administration.
The amphipathic nature of AMB significantly reduces its
solubility in water and most organic solvents. Its aqueous
solubility is improved by adding sodium deoxycholate to
produce a colloidal dispersion after reconstitution for inter-
mittent intravenous (iv) infusion (Fungizone). However,
severe side effects are associated with the administration of
Fungizone. Nephrotoxicity is the most serious chronic
adverse effect of AMB; the serum creatinine concentration
(Scr) increases in480% of patients receiving the drug (Sachs-
Barrable et al., 2008; Tonomura et al., 2009; Chuealee et al.,
2011). Additionally, AMB could induce hematological side--
effects (Brajtburg & Bolard, 1996; Yu et al., 1998; Adams &
Kwon, 2003).
There is limited information regarding AMB metabolism
and tissue distribution (Egger et al., 2001). The primary route
of its elimination is not known (Drew, 2013). AMB state
(monomers or aggregates) affects its efficacy and toxicity.
Nishi and his coinvestigators have suggested that AMB is
therapeutically active in its monomeric forms while the
existence of aggregates forms are responsible for its toxicity
(Nishi et al., 2007).
The development of parenteral AMB lipid-based formula-
tions, Abelcet, Ambisome and Amphocil, which have
shorter course of therapy (3–5 days), are effective and exhibit
lower toxicity when compared to Fungizone (Torrado et al.,
2008; Sundar et al., 2010). However, their cost has restricted
widespread use (Sachs-Barrable et al., 2008; Falamarzian &
Lavasanifar, 2010).
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AMB is also characterized by instability at gastric pH and
is unable to cross the mucosal barrier of the GI tract and enter
the blood stream. There has been some effort to formulate
AMB for oral administration. These include formulating
AMB as nanosuspensions (Kayser et al., 2003), as
Poly(lactide-co-glycolide) nanoparticles (NPs) employing
vitamin E-TPGS as a stabilizer (Italia et al., 2009; Italia
et al., 2011), as lipid-based oral formulation using Peceol
(Sachs-Barrable et al., 2008) or as liquid antisolvent precipi-
tation NPs (Zu et al., 2014). Furthermore, AMB has been
loaded to Peceol and PEG-phospholipids (iCo-009)
(Gershkovich et al., 2010; Sivak et al., 2011), to carbon
nanotubes (Prajapati et al., 2012), to gelatin-coated lipid NPs
(Jain et al., 2012), to Chitosan–EDTA conjugates (Singh
et al., 2013) and to Cubosomes (Yang et al., 2012; Yang et al.,
2014). The most recent reports include AMB liposomes
containing ceramides (Skiba-Lahiani et al., 2015) and AMB
encapsulated with a chitosan derivative (Serrano et al., 2015).
These oral drug deliveries were developed to enhance the
solubility and gastrointestinal permeability of AMB. In most
cases, these formulations failed to increase the absorption of
orally administered AMB and none of them has been
introduced to the market (Ibrahim et al., 2012; Yang et al.,
2012).
Glycyrrhizic acid (GA) is a major constituent of licorice, a
triterpene glycoside, with steroid-like, antiallergic and anti-
viral activities (Pompei et al., 1980). It has been used orally as
a sweetener and component of oriental medicines (Imai et al.,
1999; Anand et al., 2010). In the field of drug delivery, GA
possesses in vivo enhancing activity with respect to the oral
absorption of peptides such as calcitonin (Imai et al., 1999). It
is reported as non-toxic oral absorption enhancer to improve
the oral bioavailability of different drugs (Radwan & Aboul-
Enein, 2002; Chen et al., 2009; Yang et al., 2015).
We hypothesized that loading AMB to PEGylated
polylactic–polyglycolic acid copolymer (PLGA–PEG) NPs
would improve AMB solubility; decrease its toxicity (since
the drug release would be controlled from this delivery
system) and AMB aggregation (thereby further decreasing its
toxicity toward mammalian cells) while maintaining it in a
monomeric form that favors antifungal activity (Brajtburg &
Bolard, 1996; Torrado et al., 2008).
Two reports on the use of PLGA–PEG NPs as AMB
parenteral delivery systems has recently published. The first
study was concern about delivering AMB as a mannose-
anchored engineered nanoparticulate for macrophage
targeting (Nahar & Jain, 2009), while the second paper
encapsulated AMB in PLGA-PEG NPs to increase AMB
solubility and to target the macrophages of infected tissues
during visceral leishmaniasis (Kumar et al., 2015). To our
knowledge, no published data about the development of AMB
loaded to PLGA-PEG NPs for oral AMB delivery other than
by Al-Quadeib et al. (2015); the in vitro studies of the
developed formulations indicated promising oral drug deliv-
ery system with acceptable drug content and dissolution rate.
The aim of this study was to examine the practicability,
efficacy, oral bioavailability and safety of these novel AMB
formulations in rats. The in vitro AMB antifungal activity on
Candida albicans (C. albicans) of these formulations was
initially evaluated. Pharmacokinetics investigation of formu-
lations after iv and oral administrations to rats and the
feasibility of GA as an absorption enhancer to improve AMB
bioavailability was then investigated. Toxicity was examined
via an in vitro blood hemolysis test and via blood urea
nitrogen (BUN) and plasma creatinine (PCr), as indicators of
nephrotoxicity after single and multiple dosing of AMB
in rats.
Materials and methods
Materials
AMB (99.8% purity), clopidogrel, the internal standard (IS),
GA and formic acid were purchased from Sigma–Aldrich (St.
Louis, MO).
PEGylated Poly (D,L-lactide-co-glycolide) copolymer:
RGPd 50155 Diblock with molecular weight 6000 Da
(Lactic to glycolic acid molar ratio of 1:1) with 15%
polyethylene glycol and Poly(D,L-lactide): Poly(D,L-lactide)
named R 203 H Monoblock were supplied by Boehringer
Ingelheim (Ingelheim, Germany). Fungizone (AMB micelle
dispersion) was obtained from Bristol-Myers Squibb
(Montreal, Canada). RPMI 1640 medium was purchased
from Gibco/BRL (Grand Island, NY). Sabouraud Dextrose
Agar plates (RODAC) were obtained from BD Diagnostics
(Becton, Dickinson and Company, NJ). All other reagents and
chemicals were of HPLC analytical grade, and were used as
received. Water was deionized and purified by a Milli-Q
Reagent Grade water system (Millipore Corporation,
Bedford, MA).
Preparation of AMB-loaded PLGA-PEG copolymer
AMB loaded to PLGA-PEG was formulated according to Al-
Quadeib et al (2015) with modification through addition of
GA during formulation or prior to administration as shown
below. Table 1 shows the criteria of the selected AmB NPs,
from previous study; having a narrow size distribution with
smallest possible mean particle size, highest drug encapsu-
lation efficacy and drug release within 24 h. Physicochemical
characterizations (particle size analysis, FTIR, DSC and
dissolutions were done in our previously published work (Al-
Quadeib et al., 2015).
AMB loaded to PLGA–PEG NPs formulation (C6) was
selected as the base formulation for this study and is named
Table 1. The characteristics of the selected formulations.
Parameter
Formulation Polymer
Drug content,
mg/batch
Mean particle
size, nm
Drug encapsulation
efficacy, %
Drug release
within 24 h, %
F1 PLGA-PEG 20 23.8 ± 4.8 48.3 ± 4.2 61.2 ± 3.2
F2 PLGA-PEG 40 25.3 ± 2.7 56.5 ± 3.9 59.4 ± 5.7
F3 PLA 40 539.9 ± 51.1 27.2 ± 3.2 42.8 ± 2.6
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F1. When GA was added to F1 just prior to administration the
formulation is called F1-GA-out-1 and F1-GA-out-2, where, 1
and 2 refer to the percentage of GA added. When GA 2%
(w/v) was added to the organic phase during F1 preparation,
the resulted formulation is called F1-GA-in-2.
F2 was prepared by doubling the amount of AMB in the
formulation C6. When GA was added during preparation, the
formulation is called F2-GA-in-2, while F2-GAout-2 is the
same composition but the GA was added just prior to
administration. To investigate the feasibility of PLGA-PEG
NPs versus non-PEGylated polymer, PLA, AMB loaded to
PLA NPs formulation (F3) was prepared by the same
technique of C7. All formulations were prepared at least in
triplicate.
In vitro antifungal activity
Candida albicans (ATCC 90028) (C. albicans) was used for
testing the efficacy of AMB in vitro. The minimum inhibitory
concentrations (MICs) of AMB in Fungizone, F1 and F2
were determined by broth dilution according to the National
Committee for Clinical Laboratory Standard ‘‘NCCLS docu-
ment M27-A, (Standards, 2002)’’. Briefly, C. albicans cell
suspensions of 1 106 cells/ml were diluted 1:50 in RPMI-
1640 growth medium and 100 ml dispensed into a microliter
tray containing a serial concentration of AMB 0.05–1.5mg/
ml. A solution of 5 mg/ml was prepared in DMSO for free
AMB and in water for Fungizone, F1 and F2 immediately
before use. The tray was incubated for 24 and 48 h at 37 C.
The yeast were grown on Sabouraud Dextrose Agar (SDA)
plates and inoculated into RPMI 1640 broth medium to yield
a final inoculum concentration of 104 yeast cells/ml (checked
by doing a viable colony count on SDA plates). Two wells
containing drug-free medium and inoculum were used as
control. The inoculated plates were incubated at 35 C for
24 h. The growth in each well was estimated visually. The
MIC was defined as the lowest drug concentration (MIC) that
resulted in complete inhibition of visible growth. The MIC
was recorded to be the lowest concentration of the AMB that
prevented visible growth of C. albicans and expressed in mg/
ml. The end-point was determined as the concentration to
produce optically clear wells (MIC-0).
Dosing of animals and blood sampling
All the experiments were performed in accordance with the
ethical guidelines established and approved by the committee
on the use and care of laboratory animals at King Saud
University. Animals were provided from the animal house of
King Saud University. The rats were housed in polypropylene
cages in an animal facility with a 12 h light-dark cycle and
controlled temperature and humidity. Rats were given free
access to water ad libitum and fasten for 10 h before the study.
Standard rat chow was given after 2 h of dosing for the
duration of the study.
Table 2 shows the composition and method of in vivo
administration of the formulations tested in rats.
Immediately before administration, the specific weight of
the lyophilized AMB-loaded PLGA–PEG NPs were dispersed
in water either alone or in combination with GA as 1 or 2%
(w/v) as indicated. The volume of the PO colloidal dispersion
dose was 1.0 ml.
The study was conducted into two phases; phase I was
intended to examine the bioavailability of AMB in the
selected formulations while phase II was designed to inves-
tigate the toxicity of AMB in these formulations as shown
below.
After animals dosing, blood samples (600ml) were with-
drawn from the venous-orbital plexus from each rat in
heparinized tubes. Carbon dioxide was used to slightly
anesthetize the animals during blood sampling. Plasma
samples were separated by centrifugation at 4000 rpm for
15 min and were stored at 20 C prior to drug assay.
Bioavailability study
Fifty-four albino Sprague-Dawley male rats (353.2 ± 26.6 g)
were randomly divided into nine groups (I–IX, n¼ 6) and
were dosed according to Table 2. Blood samples from the
same rats were collected at 0, 1, 3, 6 and 0.5, 2, 4, 8, 24 h after
drug administration in two different occasions, separated by
3 weeks.
Nephrotoxicity and histopathological studies
The selected formulations of AMB loaded to PLGA-PEG NPs
for the in vitro efficacy and in vitro/in vivo toxicity
investigations were F1 and F2, which contain 20 and 40 mg
of AMB, respectively, without any addition of GA.
Fifteen albino Sprague-Dawley rats with 200–300 g
weight were randomly divided into five groups (1–5),
(n¼ 3). Group-1 was kept as control without any treat-
ment; group-2 received iv blank NPs with no AMB; group
3 was given Fungizone (1.0 mg/kg) as a slow iv injection
Table 2. The composition, dose and route of administration of the selected formulations.
Animal group
Route of
administration Formulation Carrier/polymer Drug amount, mg GA % IN GA % OUT Dose mg/kg
I PO Fungizone Sodium deoxycholate 50 – – 10
II iv F1 PLGA–PEG 20 – – 1
III PO F1 20 – – 10
IV PO F1-GA-out-1 20 – 1 10
V PO F1-GA-out-2 20 – 2 10
VI PO F1-GA-in-2 20 2 – 10
VII PO F2-GA-in-2 40 2 – 20
VIII PO F2-GA-out-2 40 – 2 20
IX PO F3 PLA 40 – – 20
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in the tail vein; group-4 received iv administration of F1
(1.0 mg/kg) while group-5 received iv administration of F2
(1.0 mg/kg).
After 24 h post first dose, blood samples were collected
from each rat as the single dose samples (SD) experiment.
The animals were received daily the same treatment for
7-days and 24 h post-the 7th dose, blood samples were
collected for the multiple dose (MD) experiment.
BUN and PCr were measured using an automatic analyzer
7180 (Hitachi High- Technologies Co., Tokyo, Japan) after
the single and multiple dosing administrations.
For histopathological analysis, one kidney from each rat
was fixed in neutral buffered 10% formalin for 48 h,
bisected and embedded in paraffin. Sections of 5.0 mm
thickness were cut from each kidney, and stained with
hematoxylin and eosin. For histopathological analysis of liver,
a piece of median lobe from the livers were removed from
each rats and placed immediately in 10% neutral buffered
formalin. Sections of 5.0 mm thickness were cut and stained
with hematoxylin and eosin similarly to kidney tissue.
In vitro hemolytic activity of AMB
In vitro hemolytic activity of AMB-loaded to PLGA-PEG NP
of the selected formulations (F1 and F2) were assessed using
isolated rat red blood cells (RBCs) according to Jain and
Kumar (Jain & Kumar, 2010). Briefly, blood samples from
healthy Sprague-Dawley male rats (250–350 g) were collected
by cardiac puncture under anesthesia directly into heparinized
blood collecting vials. The RBCs were separated by
centrifuging the whole blood at 3000 rpm for 15 min, the
supernatant along with buffy coat were pipetted off and
discarded. RBCs were washed thrice with 0.15 M isotonic
phosphate buffer saline (PBS) of pH 7.4 and was dispersed in
PBS to obtain 1% hematocrit. RBCs were used on the same
day for further experiments. Subsequently, 1.0 ml of the RBCs
suspension was mixed with 1.0 ml of PBS containing 20, 50 or
100mg/ml AMB equivalent formulations (Fungizone, F1 or
F2) and was incubated at 37 C in a shaking water bath at
100 rpm. The experiment was performed in triplicate. After
8 and 24 h of incubation, any hemolysis was stopped by
reducing the temperature to 0 C and un-lysed RBCs were
removed by centrifugation for 10 min at 3000 rpm. The
supernatant was collected and the erythrocyte pellet was lysed
with sterile distilled water and analyzed for the extent intact
RBCs using a spectrophotometer set at the absorption
maximum of hemoglobin (540 nm). Control RBC (2 108
cells/ml) incubated with PBS alone was used to estimate the
total hemoglobin content.
Incubation of RBCs with distilled water (as positive
control) was considered to cause 100% hemolysis. Results
were expressed as a percentage of hemolysis as given in the
following equation:
Hemolysis% ¼ AbsS  Abs0ð Þ= Abs100  Abs0ð Þ½   100
Where, AbsS is the absorbance of the sample, Abs0 is the
average absorbance of the buffer; negative control, and Abs100
is the average absorbance of the lysed samples (in purified
water; positive control). The remaining hemoglobin was
calculated as a percentage of the total content. Results are
given as the mean of one experiment representative of three
experiments carried out with each concentration in triplicate.
Chromatographic conditions
Analysis was carried out on a Waters Acquity UPLC system
(Waters, Milford, MA). The analytical method used was
adapted from Al-Quadeib et al. (2014) using rat plasma instead
of human plasma. There was no significant difference
(p40.05) between the standard curves best fit equations on
slopes, intercepts and correlation of the human and rat plasma.
The precision and accuracy of the developed LC MS/MS
method were measured for the concentration range of 100–
4000 ng/ml and was shown no significant difference among
inter- and-intra-day analysis (p40.05) in rat plasma. Excellent
linearity was observed over the investigated range with
correlation coefficient, r40.995 (n¼ 6/day). The assay was
able to detect AMB concentrations for all time points after iv
and PO administrations to rats without any modification.
Pharmacokinetics and statistical analysis
All data were expressed as the mean ± SD, if not specified
otherwise, of six replicates for the assay or the rats study. The
standard curves were calculated by linear regression without
weighting, using the equation Y¼ 0.0007X – 0.127, where Y is
the AUP ratio of the drug to the IS, 0.127 is the intercept,
0.0007 is the slope, and X is AMB concentration. The relative
standard deviation (RSD) was calculated for all values.
The plasma AMB concentration versus time data of the
rats were analyzed using a model-independent method for the
main purpose of this study (Gibaldi & Perrier, 1982). The
mean maximum concentration (Cmax) and the time to reach
Cmax (Tmax) were derived directly from the individual plasma
levels. The elimination rate constant (k) was calculated from
the slope of the regression line that best fit the terminal part
(last three to four points) of the log–linear concentration–time
profile of AMB. The terminal half-life (t1/2) was calculated
from 0.693/k. The area under the curve from time 0 to 24 h
(AUC0–24) was estimated by linear trapezoidal rule and was
extrapolated to time infinity (AUC) by the addition of Cn/k
where, Cn is concentration of the last measured plasma
sample. The total body clearance (Cl) was estimated using the
equation Cl¼ dose/AUC. The volume of distribution (V) was
determined from the equation k¼Cl/V. For oral data, the
absorption rate constant ka was estimated by the method of
residual (Tozer & Rowland, 2006). The absolute bioavail-
ability (F) was calculated by the equation (AUCpo/Dosepo)/
(AUCiv/Doseiv) after iv of F1 and oral administration of the
tested formulations listed in Table 2 while the relative
bioavailability (Frel) was calculated using (AUC, PO for-
mulation/AUC, F1-PO) Frel to Fungizone (AUC, PO for-
mulation/AUC, Fungizone-PO).
All statistical differences in data were evaluated using IBM
SPSS Statistics 21 (IBM cooperation, New York, NY). The
Student t-test was used to examine the concentration differ-
ence at each day and one-way analysis of variance (ANOVA)
was employed to assess the reproducibility of the assay and
other tests were used when needed. p50.05 was considered
significant.
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Results
Bioavailability of amphotericin B in rats
Novel oral biodegradable stealth polymeric nanoparticles of
AMB have been successfully fabricated by a modified
emulsification–diffusion technique using PLGA–PEG
(Al-Quadeib et al., 2015). Figure 1 shows the logarithmic
mean plasma concentration versus time profiles of AMB
following F1 formulation as a 1.0 mg/kg single dose (F1-iv)
and 10 mg/kg (F1-PO) to two different groups of rats via iv
and PO administrations, respectively. Fungizone, 10 mg/kg,
(Fungizone-PO) was given to a third group of rats via PO
administration for comparison.
After iv administration, a two compartment open model
was considered to adequately describe the kinetics of AMB in
rat plasma with a fast distribution, over the first 4 h, followed
by slow elimination. The oral administration of AMB as F1-
PO or Fungizone show the same trend, after the absorption
phase. However, a model-independent method was used
instead for the main purpose of this study and for simplicity
(Gibaldi & Perrier, 1982).
The pharmacokinetic parameters of the three AMB dosage
forms (F1-iv, F1-PO and Fungizone-PO) in rats are
summarized in Table 3. After iv administration of F1-iv,
AMB shows a relatively long elimination t1/2 ranging from
one to two days in rats due to its low Cl (8–23.2 ml/h/kg) and
large apparent volume of distribution in the range of 552.7–
806.3 ml/kg.
Although the iv dose was one tenth the PO doses of either
F1-PO or Fungizone PO, F1-iv shows a pronounced higher
plasma concentration of AMB (p50.05). A statistically
significant higher Cmax of AMB was observed following
F1-PO than following Fungizone-PO administrations. The
observed mean plasma AUC0–24 h and AUC0–1 after F1-PO
was about 63.7% and 36.4%, respectively, higher than that of
Fungizone-PO. The bioavailability (F) of F1-PO was 36.4%
higher than that of Fungizone PO due to the improvement of
AMB release and absorption when loaded to PLGA-PEG but
the results were not satisfactory.
To investigate the effect of GA as an absorption enhancer,
F1 and F2 were given to rats with GA, added just prior to the
administration or were included in the organic phase during
AMB loaded to PLGA-PEG NP preparation. AMB mean
plasma concentration–time profile after single oral doses of
AMB-loaded PLGA–PEG formulations with and without
the addition of the absorption enhancer GA are depicted
in Figure 2 and the pharmacokinetic parameters are presented
in Table 3.
Cmax after F1 without GA was 1.6 times that after
Fungizone (p50.05). A significant increase (p50.05) in
AMB Cmax (2.3-fold) with 4.3-fold increase in AUC (332.3%)
was observed after the addition of 1% of GA to the PO
Figure 1. Mean plasma AMB concentration–
time profiles after intravenous administration
of 1.0 mg/kg of F1-iv and oral administra-
tions of 10 mg/kg of F1-PO and Fungizone
to rats (n¼ 6).
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Table 3. Pharmacokinetic parameters of AMB after iv and oral administrations of AMB-loaded PLGA-PEG
formulations and fungizone in rats (n¼ 6).
Tested parameters F1-iv F1-PO Fungizone-PO
Dose, mg/kg 1 10 10
Cmax, ng/mL – 480.2 ± 38.7 298.2 ± 28.3
AUC0–24h (mg.h/l) – 6100 ± 514.9 3720.8 ± 617.5
AUC (mg.h/l) 84211.2 ± 33935 12325.1 ± 1511.3 9832.4 ± 1657.5
k (h1) 0.0208 ± 0.0084 0.0298 ± 0.0060 0.0019 ± 0.0015
Cl (ml/h/kg) 13.8 ± 6.1
t1/2 (h) 38.1 ± 14.8 24.0 ± 4.4 35.3 ± 2.6
V (ml/kg) 666.1 ± 109.7
F – 0.0146 0.0117
Frel Fungizone – 1.3
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formulations, just prior to the administration. This is an
indication of the efficiency of GA as an absorption enhancer
for AMB.
Increasing the GA content from 1% (F1-GA-out-1) to 2%
(F1-GA-out-2), showed a significant increase in Cmax (2.97
fold) and in AUC (390.7%) compared to F1 formulation
without GA. Further increase in GA content to 3% showed no
significant change in either Cmax or AUC of AMB profile,
data not shown. Therefore, GA at 2% was selected as the
optimum amount to be added to the tested formulations.
It was noticed that the addition of GA during preparation
process (F1-GA-in-2) or just prior to the administration (F1-
GA-out-2) showed no significant difference (p40.05) in the
AUC (13.5%), with a 27.9% increase in the Cmax value. This
is an indication that the efficacy of GA as an absorption
enhancer for AMB is not changed either GA added just prior
to administration or during the preparation.
Doubling the amount of the AMB in the formulation
from 20 mg (F1) to 40 mg (F2) resulted in doubling the AUC
of F1-GA-in-2 and F2-GA-in-2 (20216.2 ± 1593 and
38808.6 ± 4033 mg.h/l, respectively). The same trend was
observed when GA was out, therefore, AMB shows linear
kinetic within the tested amount in the formulation.
It should be mentioned that for each tested formulation, in
rats, the value of the absorption rate constant of AMB loaded
to PLGA-PEG NPs, ka, was much greater than the value of
elimination rate constant k, which indicates a fast release of
AMB with no sign of the flip-flop’ model (Gibaldi & Perrier,
1982). The highest ka among the tested formulations was F1-
GA-in compare to the others. Therefore, the addition of GA
during preparation of F1 resulted in higher release of AMB.
The absolute bioavailability (F) of AMB from tested AMB
loaded to PLGA-PEG NP formulation was calculated,
Table 4. Upon the addition of 2% GA during the formulations,
the F was improved from 1.5 to 10.5% (sixfolds). The Frel was
improved from 332 to 616.5% and 25 to 800% after the
addition of GA compared to F1-PO and Fungizone,
respectively. The highest improvement in Frel was detected
in formulation F1-GA-in-2.
Although the iv dose was one tenth the PO doses of either
F1-PO or Fungizone-PO, F1-iv shows a pronounced higher
plasma concentration of AMB (p50.05). This could be
attributed to either incomplete absorption of AMB from these
formulations or because the drug was subjected to a
significant first pass metabolism in the liver after absorption
from the GI tract.
Moreover, loading AMB to non-PEGlyated polymer (poly
(D, L-lactide-co-glycolide, RG 502 H), showed no absorption
of AMB at all the time points. This is a confirmation of the
importance of the PEG in PLGA polymer to promote the
absorption of AMB after PO administration.
In vivo nephrotoxicity
Nephrotoxicity is the most serious adverse effect of AMB
after chronic exposure; the Scr increases in more than 80% of
patients receiving this drug (Sabra and Branch, 1990;
Tonomura et al., 2009). In the conventional solution formu-
lation, the drug is present as micelles. As soon as the drug
solution enters the bloodstream it separates from the micelles
and this appears to be critical to subsequent nephrotoxic
effects. The incidence of AMB nephrotoxicity is very high,
varying in studies between 49% and 65% (Deray, 2002).
Nephrotoxicity is defined in most studies as a doubling of
baseline creatinine (Cr) levels (100% increase from the serum
baseline) or greater than 2.5 mg/dl in human (Miller et al.,
2004).
The present investigation examined two biomarkers (BUN
and PCr) of renal injury. No mortality was observed after iv
doses in any of the rats during the study. Relevant changes in
serum chemistry are summarized in Figures 3 and 4. In the
rats treated with iv Fungizone, there was a significant
(p¼ 0.003 and p¼ 0.001) increase in BUN and PCr levels,
respectively, as compared to control rats, indicating that
Fungizone administration resulted in nephrotoxicity upon
Figure 2. Mean plasma AMB concentration–
time profiles following single oral adminis-
tration of 10.0 mg/kg of AMB-loaded
PLGA-PEG formulations in rats (n¼ 6).
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administration as a single or multiple doses. However, iv
administration of AMB-loaded to PLGA-PEG NPs led to non-
significant difference (p40.05) in BUN and PCr levels in the
rats, as compared to control rats, indicating lower nephrotox-
icity by AMB when loaded to PLGA-PEG NPs as compared
to Fungizone.
PCr were in the range of 0.31–0.34 mg/dl for both
formulations, which is within the normal range for rat
plasma. Therefore, AMB loaded to PLGA-PEG NPs,
showed minimal renal effects than Fungizone over the
short duration of treatment.
The histopathological analysis of kidney tissue after iv
administrations of the NPs formulations of AMB and
Fungizone, did not confirm any unusual sign of necrosis
in all treated groups except in the Fungizone treated group.
It showed a distinctive necrosis of various degree as presented
in Figure 5, which has been approved by the PCr results in the
same study. As a conclusion, all the iv administrations of the
developed AMB-loaded to PLGA–PEG Diblock copolymer
investigated, showed minimal renal damage compared to the
reference formulation Fungizone, over a short duration of
treatment.
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Figure 4. Plasma Cr, mg/dL, (mean ± SD) after single and multiple iv
doses (5 mg/kg) of AMB and AMB loaded to PLGA-PEG NP to rats
(n¼ 3).
0.00
10.00
20.00
30.00
40.00
50.00
60.00
Control Fungizone F1 F2
BU
N
 (m
g/
dL
)
Single Dose
Mulple Dose
Figure 3. BUN, mg/dL, (mean ± SD) after single and multiple iv doses
(5 mg/kg) of AMB and AMB loaded to PLGA-PEG NP to rats (n¼ 3).
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In vitro hemolysis test
In order to determine the effect of the NPs of AMB on
hemolytic profile, the RBS lysis induced by AMB NP
selected formulations were compared with the Fungizone.
The extent of hemolysis induced after incubation of RBCs
with F1 and F2 formulations of AMB-NP in comparison with
Fungizone is depicted in Figure 5. The hemolysis was high
(84%) in the case of Fungizone at 100 mg/ml and 43% at
20 mg/ml. Therefore, it seems that Fungizone is likely to be
toxic, even at the lowest concentration used in the experiment.
At a similar concentration AMB loaded to PLGA–PEG NPs
formulations showed negligible hemolysis. The results in
Figure 6 also indicate that the hemolysis was dose-dependent.
Regarding the degree of hemolysis, the tested formulations
were classified as low hemolytic toxicity 4 to 8 times hemolysis
reduction in comparison with Fungizone, F2 formulation
showed the lowest hemolysis reflects a better control over the
rate of AMB diffusion from these selective formulations over
the Fungizone. After 24 h incubation, similar results were
obtained as that after 8 h incubation, indicating that the releases
of AMB from these formulations is slow and it seems that
PLGA-PEG NP imparts a protective effect to AMB in
preventing the RBC lysis of these formulations.
In vitro antifungal activity
Table 5 shows the antimicrobial activity of pure AMB,
Fungizone and the selected formulations of AMB loaded to
PLGA-PEG NP in C. albicans after 24 and 48 h incubations.
The MIC-0 for pure AMB was found to be 0.5mg/ml after
24 h and 1.0 mg/ml after 48 h incubation. Similar results are
obtained by others (Nishi et al., 2007). Meanwhile, the MIC-0
for AMB loaded to PLGA–PEG NP formulations was reduced
by  fourfold.
Discussion
Several reports show that parenteral administrations of AMB
polymeric nanoparticles formulations, have antifungal effi-
cacy and lower toxicity with increase accessibility of the drug
to organs and targeted tissue (Amaral et al., 2009; Laniado-
Laborı´n & Cabrales-Vargas, 2009; Souza et al., 2015). It was
also reported that some carriers added during the formulation
process affect the aggregation state and hence AMB activity
(Legrand et al., 1992). Barwicz et al. have demonstrated the
ability of surfactants to reduce the toxicity of AMB via
1
3 4
2
Figure 5. Typical kidney tissue alterations verified in rats treated with AMB or its equivalent dose as 1.0 mg/kg of body weight as iv administration of
different Amb-PLGAPEG copolymer. 1) normal kidney tissue; 2,3,4) Fungizone f1 and f2, respectively, varying degree of nephrotoxicity necrosis
related to iv administration of iv doses (5 mg/kg).
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Figure 6. In vitro mean RBCs hemolysis following incubation of RBC
with Fungizone and different AMB-NPs formulations at concentrations
of 20, 50 and 100 mg/ml (n¼ 3).
Table 5. Checkboard assay of AMB against C. albicans (n¼ 6).
Tested form MIC-0 (mg/ml) after 24 h MIC-0 (mg/ml) after 48 h
AMB 0.5 ± 0.01 1.0 ± 0.01
Fungizone 0.5 ± 0.01 1.0 ± 0.01
F1 0.125 ± 0.01 0.125 ± 0.01
F2 0.125 ± 0.01 0.125 ± 0.01
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decreasing the aggregation state of the drug (Barwicz et al.,
1992; Adams and Kwon, 2003).
Currently, PLAG and PLGA-PEG are being used to
improve the release rate of different classes of drugs from
NPs systems intended for both parenteral (Alle´mann et al.,
1998; Huh et al., 2003; Packhaeuser et al., 2004; Cheng et al.,
2007; Saadati & Dadashzadeh, 2014; Teekamp et al., 2015)
and oral administrations (Yoo & Park, 2001; Garinot et al.,
2007; Fernandez-Carballido et al., 2008; Khalil et al., 2013;
Yan et al., 2015). The ability of PLGA–PEG to enhance
bioavailability of hydrophobic drugs, has been demonstrated
for different classes of drugs. Curcumin potential efficacy is
limited by its lack of solubility in aqueous solvents and poor
oral bioavailability. PLGA–PEG NPs were able to increase
curcumin bioavailability by 3.5-fold compared to curcumin
loaded PLGA NPs alone (Anand et al., 2010).
GA and its derivatives have been utilized in enhancing
drug absorption (Tanaka et al., 1992; Imai et al., 1999;
Radwan & Aboul-Enein, 2002; Cho et al., 2004; Anand et al.,
2010). Significant enhanced rectal absorption of AMB
suppositories in rabbits following GA addition in comparison
to formulation containing no GA (Tanaka et al., 1992; Anand
et al., 2010). Insulin nasal spray formulations for nasal
delivery containing GA showed improved bioavailability
(Khalil et al., 2013). Additionally oral delivery of heparin is
achieved by addition of GA (Motlekar et al., 2006).
Comparing the relative bioavailability of each tested
formulation to F1-PO without GA, resulted in a maximum
improvement of 798% in Frel to Fungizone, which is better
than the outcome of the published investigations as presented
in Table 6. Sachs-Barrable et al. (2008) was exceptional in
improving the relative F of AMB but in different system and
dose of Fungizone used.
AMB nephrotoxicity is manifested by renal insufficiency
due to glomerular and vascular disease in addition to
abnormalities in tubular function. Acute AMB-induced
nephrotoxicity is characterized by increased BUN and
increased PCr levels. BUN is an important biochemical
marker, which is routinely evaluated as an indicator of clinical
renal function. Abnormally high BUN levels indicate the
dysfunction or damage to the kidney. Similarly, PCr is another
reliable marker of renal function. Creatinine, the end product
of muscle metabolism, is filtered and excreted by the kidneys.
Elevated PCr levels is indicative of renal dysfunction (Italia
et al., 2009; Tonomura et al., 2009).
The reduced toxicity of AMB-NP observed could be due to
the fact that AMB was slowly released from AMB-NP than
from the deoxycholate micelles of Fungizone. AMB is
known to induce vasoconstriction, which leads to a decrease
of blood flow in the kidney. The observed reduction in the
PCr is believed to be caused by a decrease in blood pressure
that is associated with a decrease in blood flow in the
glomerulus (Tasset et al., 1992; Tiyaboonchai et al., 2001;
Risovic et al., 2003; Nahar et al., 2008; Italia et al., 2009;
Tonomura et al., 2009; Belkherroubi-Sari et al., 2011).
It is reported that AMB is highly toxic in its aggregated
state than in its monomer form (Brajtburg & Bolard, 1996;
Nishi et al., 2007). In solution, AMB exists in three different
forms; monomers, oligomers and aggregates. The soluble
form of AMB exists in monomeric form (Brajtburg & Bolard,
1996; Nishi et al., 2007).
The ratio of absorbance at 348 nm to 409 nm is reported to
give the extent of aggregation in AMB (Legrand et al., 1992).
Barwicz et al. (1992) report the ratio to be 2 for aggregated
species. Most of the AMB formulations have greater A348/
A409 values. For instance, Fungizone has a value of 2.9
while Ambisome has a value of 4.8 (Mullen et al., 1997).
For AMB-loaded PLGA-PEG, the value obtained was less
than1.14 showing that AMB was not aggregated in the novel
oral formulation. Therefore, assessment of hemolytic toxicity
seems to be a prerequisite while developing any formulation
of AMB.
The lack of hemolysis activity may reflect the release of
monomeric AMB from AMB-loaded PLGA-PEG copolymer
as opposed to Fungizone, which release both aggregated and
monomeric forms of the drug (Yu et al., 1998; Adams &
Kwon, 2003; Brajtburg & Bolard, 1996). Therefore, the low
hemolysis of all AMB-NP as shown in Figure 6 might be
attributed to the encapsulation of a nanoaggregate form of
AMB, and slow diffusion of AMB from the conjugated
polymer. Another explanation, is that during formulation,
AMB was added in an aqueous polymer phase that was
acidified with 5N HCL (pH 3) (far from the pKa of the drug;
3.7 and 10), thus precluding self-association or aggregation.
Fungizone caused more extent of hemolysis because
Fungizone formulation consist of micellar dispersion of
AMB with sodium deoxycholate, which act as surfactant and
can induce hemolysis itself in addition to the hemolysis
caused by AMB. Fungizone is well-known for causing
hemolysis mainly due to active hemolysis by pore formation
and changing electrolyte balance in erythrocytes (Yu et al.,
1998; Fukui et al., 2003; Bang et al., 2008; Nahar et al., 2008;
Italia et al., 2009; Falamarzian & Lavasanifar, 2010; Jain &
Table 6. Relative bioavailability of AMB in rats, after PO administration of various AMB-loaded NPs in different formulations, in
comparison to Fungizone.
Reference Formulation/Polymer
Dose of fungizone,
mg/kg
AMB Dose in
tested formulation,
mg/kg Frel to fungizone %
Current study Copolymer (PLGA-PEG) 10 10 798
(Yang et al., 2012) Cubosomes 10 10 285
10 20 702
(Italia et al., 2009) PLGA 10 10 693
(Sachs-Barrable et al., 2008) Peceol/AMB 50 50 2197
50 5 8506
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Kumar, 2010; Shao et al., 2010; Sheikh et al., 2010; Asghari,
2011).
AMB at concentrations 40.5 to 1-fold the MIC has a
fungicidal activity, while AMB at concentrations50.5 to 1-
fold the MIC has a fungistatic activity, a finding that has been
described previously (Tasset et al., 1992; Pfaller & Barry,
1994; Risovic et al., 2003; Belkherroubi-Sari et al., 2011).
The MIC of AMB loaded to PLGA-PEG NP against
C. albicans was reduced two to three-fold compared with
free AMB. Therefore, the prepared AMB-NPs formulations
have high therapeutic efficacy and are useful for the treatment
of fungal infection including candidiasis.
Conclusion
In conclusion, an innovative AMB oral formulation was
developed which would improve the patient adherence due to
the potential reduction of AMB adverse side effects especially
nephrotoxicity and induction of hemolysis. PEGylated poly-
mer (PLGA-PEG) enhances the oral absorption of AMB
compared to Fungizone. On a cellular level, AMB loaded to
PLGA-PEG copolymer showed potent activity against in vitro
C. albicans with no pathological abnormalities were observed
in rats’ kidney tissues. A further study is needed to investigate
the in vivo efficacy of the developed formulation.
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